The Association for Clinical Oncology (ASCO) submitted comments to the Department of Defense (DoD) in response to the TRICARE Coverage and Payment for Certain Services in Response to the COVID–19 Pandemic interim final rule. The rule allows TRICARE to reimburse providers for audio-only services during the COVID-19 Public Health Emergency (PHE).
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB‑H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.
On June 12, 2020, the U.S. Department of Health and Human Services (HHS) released a final rule establishing changes to Section 1557 of the Affordable Care Act (ACA), which prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs or activities.
On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
On June 10 ASCO’s CancerLinQ® launched the SmartLinQ™ QOPI® Certification Pathway, an application that empowers oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative (QOPI) Certification Program, a three-year certification recognizing practices’ commitment to high-quality care for outpatient oncology practices.
The Association for Clinical Oncology (ASCO) Board approved its 2020 Advocacy Priorities, which will help ensure that patients with cancer and survivors have access to value-based, high-quality cancer care.
The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced additional distributions from the Provider Relief Fund to eligible Medicaid and Children's Health Insurance Program (CHIP) providers that participate in state Medicaid and CHIP programs.
The Association of Community Cancer Centers (ACCC) and the American Society of Clinical Oncology (ASCO) held a special live webcast on the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry). A recording is now available.
The Centers for Medicare & Medicaid Services (CMS) released Part 1 of its final rule outlining changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) programs for contract year 2021. Due to June 1 bid deadlines for both the MA and Part D 2021 plan years, CMS finalized only a subset of the agency’s proposed policies at this time, which the Association for Clinical Oncology (ASCO) submitted comments regarding six provisions in the proposed rule.
Oncology practices can now participate in the American Society of Clinical Oncology’s (ASCO) 2020 Survey of Oncology Practice Operations (SOPO). The survey, which opens today, gives practices a deeper look at a variety of management topics from revenues to staffing levels, and reviews the current state of business and operational issues in oncology. This survey is part of ASCO’s continued efforts to help oncology practices navigate the evolving cancer care delivery system.
The Association for Clinical Oncology (ASCO) submitted a letter to the Centers for Medicare & Medicaid Services (CMS) regarding the Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC) interim final rule. In the letter, ASCO applauds the temporary flexibilities CMS has established to promote efficiency and streamline processes for healthcare providers during the COVID-19 pandemic and the public health emergency (PHE).
The Centers for Medicare & Medicaid Services Innovation Center (CMMI) announced new flexibilities and adjustments to its current and future alternative payment models in response to the COVID-19 Public Health Emergency (PHE). Of note for the cancer community, CMMI made changes to the Oncology Care Model, such as payment methodology, quality reporting, and the timeline.
On June 3, 2020, ASCO President Dr. Lori J. Pierce released a statement "Responding to Racism and Health Inequality as a Cancer Care Community".